Significant Shareholders
%
| Shareholder | No. of Ordinary Shares | No. of Multiple-Vote | Shares % of Share Capital | of Voting Rights |
|---|---|---|---|---|
| G.S.M. S.r.l. | 3.115.228 | 259.881 | 50,37% | 58,01% |
| La Farmaceutica S.p.A. | 1.080.272 | 90.119 | 17,47% | 20,12% |
| First SICAF S.p.A. | 800.000 | – | 11,94% | 8,12% |
| Mercato | 1.354.500 | – | 20,22% | 13,75% |
| Totale | 6.350.000 | 350.000 | 100,00% | 100,00% |
Pursuant to the Euronext Growth Milan Issuers’ Regulation, shareholders who hold an interest in the share capital of Più Medical S.p.A. (the “Issuer”) are required to notify the Issuer of any “material change”, i.e., the reaching or exceeding of the thresholds of 5%, 10%, 15%, 20%, 25%, 30%, 50%, 66.6% and 90% of the Issuer’s share capital, as well as any decrease below the above thresholds (the “Material Change”). For the purposes of these disclosure obligations, “share capital” means both the total number of voting rights and the number of ordinary shares held, and both notifications are required.
For the purposes of calculating the holdings of a so-called significant shareholder—i.e., a shareholder who holds 5% or more of a class of shares admitted to trading on Euronext Growth Milan (excluding treasury shares), pursuant to the major shareholdings regime under the Italian Consolidated Law on Finance (Testo Unico della Finanza)—the following must be taken into account: (i) the shareholdings held by the shareholder (even if the voting rights are exercised by or attributed to third parties); (ii) the shareholdings in respect of which voting rights are exercised by or attributed to the shareholder; (iii) the shares held by nominees, fiduciaries, controlled companies, or in respect of which voting rights are exercised by or attributed to such persons; and (iv) the shares collectively contributed under a shareholders’ agreement concerning the exercise of voting rights in the Issuer.
For the purposes of the above, promptly and in any event within four trading days of the transaction that triggers the obligation (regardless of the settlement date) or of the day on which the significant shareholder becomes aware of events resulting in changes to the Issuer’s share capital, the significant shareholder must notify the Issuer of:
- its identity
- the date on which the Issuer was notified;
- the date on which the Material Change in the shareholding occurred;
- the nature and size of the significant shareholder’s interest in the transaction (in the event of the issuance of multiple-vote shares, the number of voting rights and the number of ordinary shares held).
The notice must be sent via certified email (PEC) to the following address: investorrelations@piumedical.com and, for information purposes, to piumedical@legalmail.it